|
| Tuesday, March 12, 2013 |
|
|
Cytokinetics to Present at 25th Annual Roth Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 25th Annual Roth Conference on Monday, March 18, 2013 at 9:00 AM Pacific Time in Salon 5 of the Ritz Carlton in Laguna Niguel, California. more info >> |
|
| Saturday, February 23, 2013 |
|
|
Cytokinetics to Present at Upcoming Healthcare Conferences |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences. more info >> |
|
| Tuesday, February 12, 2013 |
|
|
Cytokinetics Announces Opening of COSMIC-HF, a Phase II Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Patients with Heart Failure |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to enrollment of a Phase II clinical trial of oral formulations of omecamtiv mecarbil. more info >> |
|
| Friday, February 8, 2013 |
|
|
Cytokinetics to Present at BIO CEO and Investor Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 11, 2013 at 1:30 p.m. Eastern Standard Time in the East Foyer Room of the Waldorf Astoria Hotel in New York, New York. more info >> |
|
|
Cytokinetics Announces Changes to Its Board of Directors |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Steve Dow has provided notification that he will not stand for re-election to the Company's Board of Directors at its Annual Meeting of Shareholders to occur on May 22, 2013. more info >> |
|
| Wednesday, February 6, 2013 |
|
|
Cytokinetics, Incorporated Reports Fourth Quarter 2012 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues of $2.2 million for the fourth quarter of 2012. more info >> |
|
| Wednesday, January 30, 2013 |
|
|
Cytokinetics to Announce Fourth Quarter Results on February 5, 2013 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report fourth quarter results on Tuesday, February 5, 2013 at 4:00 PM Eastern Time. more info >> |
|
| Saturday, January 26, 2013 |
|
|
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance |
| Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater. more info >> |
|
| Wednesday, December 19, 2012 |
|
|
Cytokinetics, Incorporated Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market |
| Cytokinetics, Incorporated (NASDAQ: CYTK), announced today that NASDAQ has approved the Company's request to voluntarily transfer the listing of its shares of common stock from The NASDAQ Global Market to The NASDAQ Capital Market. more info >> |
|
| Wednesday, December 12, 2012 |
|
|
Cytokinetics Highlights Progress of Activities Directed to Muscle Biology at Today's Research & Development Day |
| Cytokinetics, Incorporated (Nasdaq: CYTK) is scheduled today to provide a corporate update on the company's research and development pipeline and will be highlighting its focus to advancing novel, internally-discovered drug candidates that are directed to the biology of muscle function and contractility. more info >> |
|
|
|
|
